title: Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
abstract: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22. Imatinib mesylate is a potent and selective inhibitory of the BCR/ABL tyrosine kinase. Imatinib is a first choice of treatment of chronic phase CML. It has also shown activity in patients with CML in accelerated or blastic phases. However, the penetration of the drug and its active metabolites into the central nervous system (CNS) is poor. Therefore, the CNS is sanctuary site for malignant cells in patients treated with imatinib. Herein, we report a patient with CML in accelerated phase that developed central nervous system disease while on imatinib mesylate therapy.
authors.affiliation: Internal Medicine, Department of Hematology-Oncology, Dicle University, 21280, Diyarbakir, Turkey. draaltintas@dicle.edu.tr
authors.forename: Abdullah
authors.initials: A
authors.lastname: Altintas
authors.forename: Timucin
authors.initials: T
authors.lastname: Cil
authors.forename: Ilhan
authors.initials: I
authors.lastname: Kilinc
authors.forename: Muhammet Ali
authors.initials: MA
authors.lastname: Kaplan
authors.forename: Orhan
authors.initials: O
authors.lastname: Ayyildiz
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D023981:Sarcoma, Myeloid / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D003561:Cytarabine; D003907:Dexamethasone; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D008727:Methotrexate